Search - tctmd.com

Displaying 1 - 20 of 159

Sort: Relevancy | Date

News Daily News

Absorb BVS Meets Performance Goal in Diabetic Patients, but Is It Enough to Justify a Broader Label?

Yael L. Maxwell

December 23, 2016

Presentation

Efficacy and Safety of the Absorb Bioresorbable Scaffold for Treatment of Patients With Diabetes Mellitus: Absorb Diabetic Substudy

Presenter: D. Kereiakes

December 23, 2016

News Industry News

Micell Technologies Announces First Patient Enrolled In Landmark Registration Trial of MiStent In Japan

November 29, 2016

News Conference News TCT 2016

RIBS VI: El SVB Absorb es Seguro en el Manejo de la Reestenosis Intra-stent pero No Supera al Stent Metálico Xience

Michael O'Riordan

November 08, 2016

News Conference News TCT 2016

RIBS VI: Absorb BVS Safe in In-Stent Restenosis but Fails to Best Xience Metallic Stent

Michael O'Riordan

November 08, 2016

News Conference News TCT 2016

RIBS VI：Absorb BVS 支架内再狭窄方面安全，但没有好过 Xience 金属支架

Michael O'Riordan

November 08, 2016

News Industry News

Positive Five-Year Clinical Data from Micell Technologies’ MiStent Presented at TCT 2016

November 03, 2016

News Conference News TCT 2016

New BRS Studies Show Promise for Second-Generation Devices With Thinner Struts

Yael L. Maxwell

October 31, 2016

News Conference News TCT 2016

‘Worrisome’ 3-Year Data From ABSORB II Raise Concerns About First-Generation Bioresorbable Stent

Michael O'Riordan

October 30, 2016

Presentation TCT 2016

ABSORB II: Three-Year Clinical Outcomes From a Prospective, Randomized Trial of an Everolimus-Eluting Bioresorbable Vascular Scaffold vs an Everolimus-Eluting Metallic Stent in Patients With Coronary Artery Disease

Presenter: David W.M. Muller, Jonathan M. Hill, Patrick W. Serruys

October 30, 2016

Presentation TCT 2016

ABSORB China: Two-Year Clinical Outcomes From a Prospective, Randomized Trial of an Everolimus-Eluting Bioresorbable Vascular Scaffold vs an Everolimus-Eluting Metallic Stent in Patients With Coronary Artery Disease

Presenter: David W.M. Muller, Jonathan M. Hill, Runlin Gao

October 30, 2016

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for August 2016

Caitlin E. Cox

September 01, 2016

News Features

The Bioresorbable Stent Story So Far: What Promise? What Price?

Michael O'Riordan

August 17, 2016

News Daily News

Absorb BVS 的 18 个月结果“令人安心”，但仍需要更长期的随访

Michael O'Riordan

August 01, 2016

News Daily News

“Tranquilizadores” Resultados a 18 Meses con el AVB Absorb Aunque Todavía Necesitamos Seguimientos Más Largos

Michael O'Riordan

August 01, 2016

News Daily News

‘Reassuring’ 18-Month Results Seen With Absorb BVS, but Longer-Term Follow-up Still Needed

Michael O'Riordan

August 01, 2016

News Daily News

TCTMD’s Top 10 Most Popular Stories for July 2016

Shelley Wood

July 28, 2016

Presentation

Mid- to Long-Term Outcomes of Patients Treated With the Absorb Bioresorbable Vascular Scaffold

Presenter: Cordula Felix

July 28, 2016

News Industry News

Tallahassee Memorial HealthCare Becomes First Hospital in Florida to Offer and Deploy First-of-Its-Kind Naturally Dissolving Heart Stent

July 14, 2016

News Daily News

Now You See It: FDA Approves Absorb Bioresorbable Scaffold

Michael O'Riordan

July 05, 2016

Advertisement

Absorb BVS Meets Performance Goal in Diabetic Patients, but Is It Enough to Justify a Broader Label?

Efficacy and Safety of the Absorb Bioresorbable Scaffold for Treatment of Patients With Diabetes Mellitus: Absorb Diabetic Substudy

Micell Technologies Announces First Patient Enrolled In Landmark Registration Trial of MiStent In Japan

RIBS VI: El SVB Absorb es Seguro en el Manejo de la Reestenosis Intra-stent pero No Supera al Stent Metálico Xience

RIBS VI: Absorb BVS Safe in In-Stent Restenosis but Fails to Best Xience Metallic Stent

RIBS VI：Absorb BVS 支架内再狭窄方面安全，但没有好过 Xience 金属支架

Positive Five-Year Clinical Data from Micell Technologies’ MiStent Presented at TCT 2016

New BRS Studies Show Promise for Second-Generation Devices With Thinner Struts

‘Worrisome’ 3-Year Data From ABSORB II Raise Concerns About First-Generation Bioresorbable Stent

ABSORB II: Three-Year Clinical Outcomes From a Prospective, Randomized Trial of an Everolimus-Eluting Bioresorbable Vascular Scaffold vs an Everolimus-Eluting Metallic Stent in Patients With Coronary Artery Disease

ABSORB China: Two-Year Clinical Outcomes From a Prospective, Randomized Trial of an Everolimus-Eluting Bioresorbable Vascular Scaffold vs an Everolimus-Eluting Metallic Stent in Patients With Coronary Artery Disease

TCTMD’s Top 10 Most Popular Stories for August 2016

The Bioresorbable Stent Story So Far: What Promise? What Price?

Absorb BVS 的 18 个月结果“令人安心”，但仍需要更长期的随访

“Tranquilizadores” Resultados a 18 Meses con el AVB Absorb Aunque Todavía Necesitamos Seguimientos Más Largos

‘Reassuring’ 18-Month Results Seen With Absorb BVS, but Longer-Term Follow-up Still Needed

TCTMD’s Top 10 Most Popular Stories for July 2016

Mid- to Long-Term Outcomes of Patients Treated With the Absorb Bioresorbable Vascular Scaffold

Tallahassee Memorial HealthCare Becomes First Hospital in Florida to Offer and Deploy First-of-Its-Kind Naturally Dissolving Heart Stent

Now You See It: FDA Approves Absorb Bioresorbable Scaffold

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content